Resource Library
Samsung Biologics Capacity Update (N-1 perfusion, PFS)
Samsung Biologics is driving the future of biomanufacturing with unmatched quality, speed, and agility. As the world’s leading CDMO with 784kL capacity, we’re expanding further with Plant 5 opening in Q3 2025 and groundbreaking innovations at Biocampus II.
Key highlights include our cutting-edge N-1 perfusion technology launching in May 2025 and advanced prefilled syringe capabilities for streamlined fill-finish solutions. These advancements reflect our commitment to meeting the evolving needs of partners and leading in large molecule manufacturing.
Samsung Biologics is driving the future of biomanufacturing with unmatched quality, speed, and agility. As the world’s leading CDMO with 784kL capacity, we’re expanding further with Plant 5 opening in Q3 2025 and groundbreaking innovations at Biocampus II.
Key highlights include our cutting-edge N-1 perfusion technology launching in May 2025 and advanced prefilled syringe capabilities for streamlined fill-finish solutions. These advancements reflect our commitment to meeting the evolving needs of partners and leading in large molecule manufacturing.